Treatment for Pulmonary Arterial Hypertension Cleared PDF Print E-mail
Thursday, 17 September 2009 14:50
taken from http://www.flickr.com/photos/dhedwards/383835919/Renal & Urology News has recently reported in its September Issue that the FDA has cleared Tyvaso (treprostinil) Inhalation Solution for the treatment of pulmonary arterial hypertension (PAH). Developed by United Therapeutics Corp., of Silver Spring, Md., treprostinil is indicated to increase walk distance in patients with New York Heart Association Class III symptoms associated with WHO Group I PAH, which includes multiple etiologies such as idiopathic and familial PAH as well as PAH associated with Scleroderma and congenital heart disease.

In the TRIUMPH-1 randomized, double-blind, 12-week, placebo-controlled clinical trial, patients taking treprostinil in four daily inhalation sessions achieved a 20-meter improvement in six-minute walk distance compared with placebo recipients. The safety and effectiveness in patients with underlying lung disease has not been established. The most common side effects seen with treprostinil were cough, headache, nausea, dizziness, flushing, throat irritation, pharyngolaryngeal pain, and diarrhea.
 
More articles :

» Dog-sled Challenge To Raise Raynaud's Research Cash

Anne Mawdsley has swum with sharks, completed the Olympic bobsleigh run and driven at high speed round a rally course to raise charity cash. But later this month she takes on what could be the biggest challenge of her life - a dog sled run in...

» Scleroderma Foundation Medical Advisory Board Offers Consensus On Gleevec

® (imatinib mesylate, Novartis) is approved in the United States for the treatment of certain forms leukemias and solid tumors. The recent discovery that Gleevec® inhibits important cellular enzymes that control fibrosis led to studies to evaluate...

» Unite Against Scleroderma A Great Success

Our very first Scleroderma Awareness Walk, "Unite Against Scleroderma" was a great success. Sunday May 1st was a dream that became a reality, simply because family and friends of the Foundation also wanted the community of Trinidad and Tobago to be...

» Children Get Scleroderma Too

Juvenile is a rare childhood condition characterized by fibrosis of the skin and internal organs. Clinical manifestations of childhood Scleroderma are different from adult disease and early recognition, correct classification and treatment can...

» Facing Life's Challenges

At 57 years of age Anne Wersching doesn’t have a single wrinkle on her face.Sitting in her lounge room in Bayswater North, Ms Wersching looks well, save for a few red marks on her cheeks.But Ms Wersching has a little-known disease called...

» Thoracic Outlet Syndrome Secondary to Localized Scleroderma Treated With Botulinum Toxin Injection

Localized scleroderma is characterized by thickening of the skin and subcutaneous tissue. Depending on clinical and pathologic findings, localized scleroderma is classified into different subtypes: plaque morphea, generalized morphea, bullous...